Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyWellCare drugs-of-abuse testing Coverage & Prior A…
    Ask Trek AI about this page
    ModifiedWellCarePolicy KY.CP.MP.50

    Testing for Drugs of Abuse

    Customize your policy alerts

    Sign up for WellCare Policy KY.CP.MP.50 alerts

    Get alerted when Policy KY.CP.MP.50 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs urine and other specimen drug-of-abuse testing coverage rules for WellCare of Kentucky members, including limits on presumptive and definitive tests, prior authorization protocols, and circumstances considered not medically necessary; applies to providers submitting tests for WellCare of Kentucky enrollees.

    Policy Summary
    PayerWellCare
    PolicyTesting for Drugs of Abuse
    Policy CodePolicy KY.CP.MP.50
    Change TypeMaterial revisions to coding, PA timeframe, and scope (definitive testing only)added and removed HCPCS codes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests up to 10 business days after specimen collection when requesting definitive testing beyond annual limits.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Revised policy to state that HCPCS codes G0482 & G0483 are not medically necessary, and to reflect a 10 day post-collection authorization period.

    Added HCPCS codes 0011U and G0659 as medically necessary.

    Changed name of policy from Outpatient Testing for Drugs of Abuse to Drugs of Abuse: Definitive Testing and removed presumptive testing criteria to separate policy CP.MP.208.

    Added protocols that testing for children < 6 years of age is exempt from prior authorization and PA requests will be accepted up to 10 business days after specimen collection and reviewed for medical necessity.

    Corrected medical necessity statement in section I. to state that 'one' of the following must be met, instead of 'both'.

    35max presumptive/yr
    16max definitive/yr
    10 business daysPA submission window
    <6 yearsPA exempt age
    G0482/G0483HCPCS not medically necessary
    0011U, G0659HCPCS added

    Coverage Criteria and Medical Necessity

    Outpatient confirmatory/definitive testing beyond 16/year

    Medically necessary when ANY of the following groups A, B, or C are met for outpatient confirmatory/definitive testing beyond 16 in a calendar year:

    Main: Any of the following A, B, or C
    A: Documented history or suspicion of illicit or prescription drug use or noncompliance or a high probability of non-adherence to a prescribed drug regimen documented in the medical record; and all of the following subcriteria are met:
    A.1: A preliminary/presumptive drug test has been previously performed, unless no reliable test exists.
    A.2: Findings from the preliminary/presumptive (qualitative) test (positive or negative) are either: a) inconsistent with expected results as suggested by medical history, clinical presentation, or the member's/enrollee's statement after detailed discussion; or b) consistent with the clinical scenario but drug class–specific assays are needed to identify the precise drug(s).
    A.3: Resolving the inconsistency is essential to the ongoing care of the member/enrollee.
    A.4: Tests are limited to the specific drug(s) or number of drug classes for which preliminary analysis yielded unexpected results.
    B: Provider expects the presumptive test to be positive (for example, member/enrollee reports recent use), and all of the following subcriteria are met:
    B.1: Information regarding specific substance and/or quantity is desired.
    B.2: There are established benchmarks for clinical decision making based on specific substance and/or quantitative levels.
    B.3: Tests are limited to the specific drug(s) or number of drug classes for which the presumptive test is expected to be positive.
    C: Request is for a serum therapeutic drug level in relation to the medical treatment of a disease or condition (e.g., phenobarbital level for seizure management).

    Coverage criteria and limits

    Covered when ALL of the following (policy-level summary and limits):

    Authorization exception for young children: Testing for children <6 years of age is exempt from prior authorization; prior authorization requests may be submitted up to 10 business days after specimen collection and will be reviewed for medical necessity.

    KY-specific protocol; PA window and exemption per policy revisions.

    Definitive testing analytic standards: Definitive (confirmatory) tests must utilize methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS, LC/MS), use stable isotope or other internal standards, and have method-specific calibration and matrix-matched quality control; includes specimen validity testing.

    Meets policy definition of definitive testing.

    Quantity limits without prior authorization: Up to 35 presumptive (qualitative) tests/panels and up to 16 definitive (quantitative) tests/panels are allowed per calendar year without prior authorization; requests beyond these limits require prior authorization and review against medical necessity criteria.<=35 presumptive; <=16 definitive

    Urine drug testing is excluded when performed as a condition of employment or pre-employment, or as a requirement for continuation of employment, and when performed for participation in school, community athletic, or extracurricular activities. Drug testing done for medico-legal purposes such as court-ordered screening is excluded unless specifically required by state regulations. Routine asymptomatic screening, testing as part of routine physical or administrative examinations (for example, enrollment in school, military, marriage licensure, or insurance eligibility), and same-day duplicate metabolite screening across specimen types are also excluded.

    Blanket orders and routine physician standing orders that apply to all patients are excluded; physician-defined, time-limited standing orders for specific patient profiles may be reasonable if documented in the medical record. Also excluded are billing individual definitive CPT codes when a comprehensive definitive drug testing panel is ordered, performing point-of-care (POC) presumptive testing and then ordering the same presumptive immunoassay (IA) testing from a reference laboratory, and performing presumptive IA testing and ordering additional presumptive IA testing from a reference laboratory with or without reflex testing.

    The policy excludes automatic or reflex confirmatory testing where a presumptive point-of-care test has already been performed; reflex definitive drug tests following POC presumptive testing are specifically listed as excluded. Blanket orders and physician standing orders for all patients are not acceptable mechanisms to trigger reflex or routine confirmatory testing.

    Additionally, presumptive immunoassay testing performed in a laboratory when a POC presumptive test was already done, and use of IA testing to 'confirm' results from CLIA-waived POC devices (cups, dipsticks, cards, cassettes) are considered improper bases for reflex definitive testing and are excluded from coverage.

    Urine drug testing is considered not medically necessary when provided for the exclusionary reasons listed in the policy, including employment/pre-employment screening, school or athletic participation requirements, court-ordered medico-legal screening (unless required by state regulation), asymptomatic screening, routine physicals or administrative examinations, same-day duplicate metabolite screening across specimen types, blanket orders, reflex definitive testing after POC presumptive testing, routine standing orders, billing individual definitive CPTs when a comprehensive panel is ordered, performing POC and then ordering lab-based presumptive IA testing, and specimen validity/adulteration testing.

    The policy also denotes IA testing—whether qualitative or semiquantitative—used to 'confirm' presumptive POC results as not medically necessary, and considers specimen validity/adulteration testing part of laboratory quality control rather than a separately covered medical necessity indication.

    Previously enumerated indications considered not medically necessary are restated here and refer the reader to the exclusions above. These include blanket orders, reflex definitive testing when presumptive POC testing has been performed, routine standing orders for all patients, billing for individual drugs already included in a billed panel, and using IA testing to confirm CLIA-waived presumptive POC test results.

    The policy clarifies that presumptive IA screening prior to definitive testing without a specific physician order is not medically necessary, and that presumptive laboratory IA testing ordered after POC presumptive testing is likewise not medically necessary. Providers should refer to the exclusion list for the full set of previously identified not medically necessary indications.

    When state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for any state-specific coverage rules that supersede the policy.

    For Medicare members, applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles should be reviewed prior to applying the criteria in this clinical policy to ensure consistency with Medicare coverage requirements.

    Coding — CPT/HCPCS and ICD-10 References

    Referenced CPT/HCPCS Codesmixed
    0328UPrescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites.
    80184Phenobarbital.
    80320Alcohols.
    80321Alcohol biomarkers; 1 or 2.
    80322Alcohol biomarkers; 3 or more.
    80323Alkaloids, not otherwise specified; 1 or 2.
    80324Amphetamines; 1 or 2.
    80325Amphetamine; 3 or 4.
    80326Amphetamines; 5 or more.
    80327Anabolic steroids; 1 or 2.
    1–10 of 59
    1/6
    Definitive HCPCS codes described in policy textHCPCS
    G0480Definitive drug test(s), 1-7 drug class(es), includes specimen validity testing, qualitative or quantitative
    G0481Definitive drug test(s), 1-7 drug class(es), includes specimen validity testing (alternate phrasing present in document)
    G0482Definitive drug test(s), 8-14 drug class(es), includes specimen validity testing
    G0483Definitive drug test(s), 15-21 drug class(es) or 22+ (document lists 15-21 and 22+ under G0482/G0483 descriptions)
    Added HCPCS/U-codesHCPCSCovered
    0011UHCPCS/U-code added as medically necessary
    G0659HCPCS code added as medically necessary
    CPT codes added/updatedCPT
    80367CPT/Code added to coding tables (supporting coverage criteria)
    80368CPT/Code added to coding tables
    80369CPT/Code added to coding tables
    80370CPT/Code description updated
    80372CPT/Code added to coding tables
    80373CPT/Code added to coding tables
    80372Listed multiple times in revision history
    80373Listed multiple times in revision history
    Deleted/removed CPT codesCPTNot Covered
    0143UPreviously listed as not medically necessary; removed (deleted CPT codes)
    0144UPreviously listed as not medically necessary; removed
    0145UPreviously listed as not medically necessary; removed
    0146UPreviously listed as not medically necessary; removed
    0147UPreviously listed as not medically necessary; removed
    0148UPreviously listed as not medically necessary; removed
    0149UPreviously listed as not medically necessary; removed
    0150UPreviously listed as not medically necessary; removed
    ICD-10-CM codes that support coverage criteriaICD-10
    F10.10Alcohol abuse (range of related F10 codes listed)
    F11.10Opioid-related use/abuse codes listed
    F12.10Cannabis use codes listed
    F13.10Sedative, hypnotic or anxiolytic abuse/dependence codes
    F14.10Cocaine-related use/abuse codes
    F15.10Other stimulant use/abuse codes
    F16.10Hallucinogen abuse/dependence codes
    F18.10Inhalant abuse/dependence codes
    F19.10Other psychoactive substance use/abuse codes
    F55.0Abuse of antacids (example among F55 series)
    1–10 of 11
    1/2
    inv-14: Annual definitive test limit
    Annual definitive test limit16 definitive tests/panels per calendar year
    ApplicabilityApplies to outpatient definitive (confirmatory/quantitative) DOA testing for WellCare of Kentucky members
    Authorization triggerPrior authorization required for confirmatory/definitive testing beyond the 16-per-calendar-year limit unless meeting documented medical necessity criteria (see Coverage Criteria).
    inv-15: Annual presumptive test limit
    Annual presumptive test limit35 presumptive (qualitative) tests/panels per calendar year

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization limits and operational notes

    Up to 35 presumptive (qualitative) tests/panels and up to 16 definitive (quantitative) tests/panels are allowed per calendar year without prior authorization; prior authorization is required for outpatient confirmatory/definitive testing beyond 16 per calendar year unless the request meets the medical necessity criteria in sections A, B, or C. Requests for prior authorization will be accepted up to 10 business days after specimen collection and reviewed for medical necessity.

    • PA required for outpatient confirmatory/definitive testing beyond 16 per calendar year unless criteria A, B, or C are met.
    • Up to 35 presumptive and up to 16 definitive tests allowed per calendar year without authorization.
    • PA requests will be accepted up to 10 business days after specimen collection for review.
    Prior Authorization

    KY-specific prior authorization limits and exceptions

    Kentucky-specific protocol: testing for children under 6 years of age is exempt from prior authorization; the KY policy allows up to 35 presumptive and up to 16 definitive tests without authorization and accepts PA requests up to 10 business days after specimen collection for review.

    Background and Rationale

    Urine drug testing is used to monitor adherence to controlled substance regimens and to detect misuse. Initial screening commonly uses immunoassay (IA) methods—often performed at point of care—to detect classes such as amphetamines, cocaine, cannabinoids, opioids, and phencyclidine, with other targets added per regional trends. Immunoassay screens are rapid but subject to false positives and false negatives and may underperform relative to laboratory methods.

    When precise identification or quantification is clinically necessary—for example, to resolve inconsistencies between a patient's history and presumptive test results or to inform treatment decisions—definitive (confirmatory) testing is used. Definitive testing employs analytical methods such as gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS or LC-MS/MS) that can identify individual drugs and distinguish structural isomers, and typically uses stable isotope/internal standards, method-specific calibration, and matrix-matched quality control. Definitive testing may be qualitative or quantitative and can include specimen validity testing.

    Definitions

    inv-31: Definition — Drug of abuse (DOA)
    DefinitionDrug of abuse (DOA): a drug, chemical, or plant product known to be misused for recreational purposes.
    Common DOA screening panelBasic screening typically includes amphetamine, cocaine, marijuana, opioids, and phencyclidine (PCP).
    Clinical contextTesting panels may vary by region based on epidemiologic trends and clinical need.
    inv-32: Definition — Definitive testing (GC/MS, LC/MS description)
    Definitive testing methodsGas chromatography/mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS) methods are typically used for confirmatory/definitive testing.
    PurposeUsed to separate and identify specimen components with high sensitivity and specificity; generally not used for preliminary screening due to longer turnaround and specialized equipment.
    Policy Summary
    PayerWellCare
    PolicyTesting for Drugs of Abuse
    Policy CodePolicy KY.CP.MP.50
    Change TypeMaterial revisions to coding, PA timeframe, and scope (definitive testing only)added and removed HCPCS codes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests up to 10 business days after specimen collection when requesting definitive testing beyond annual limits.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCoding — CPT/HCPCS and ICD-10 ReferencesProvider Actions, Prior Authorization, and DocumentationBackground and RationaleDefinitions

    KY-specific annual limits stated in policy.

    Not medically necessary indications: Blanket orders; reflex confirmatory testing when a presumptive point-of-care test was performed; physician standing orders for all patients; billing individual drug codes when included in a billed panel; presumptive immunoassay testing in a lab after POC presumptive testing; presumptive screening before definitive testing if presumptive testing was not ordered; and IA testing used to confirm a presumptive POC test result are considered not medically necessary.

    Explicit NMN indications added in revisions.

    ScopeIncludes presumptive qualitative DOA testing performed in outpatient settings for WellCare of Kentucky members
    Related policyPresumptive testing criteria have been moved to separate policy CP.MP.208 (see related policies).
    inv-16: Definitive tests without prior authorization
    Definitive tests without prior authorization (KY)≤ 16 definitive tests per encounter/calendar day allowed without prior authorization for WellCare of Kentucky
    KY-specific protocolKY policy reinstates that up to 16 definitive tests are allowed without authorization; prior authorization required beyond this limit unless criteria met.
    PA submission windowPrior authorization requests may be accepted up to 10 business days after specimen collection for review (per KY protocol).
    inv-17: Presumptive tests without prior authorization
    Presumptive tests without prior authorization (KY)≤ 35 presumptive tests per encounter/calendar day allowed without prior authorization for WellCare of Kentucky
    KY-specific protocolKY policy allows up to 35 presumptive tests without authorization; PA required for exceedance unless medical necessity criteria met.
    PA exceptionsTesting for children under 6 years of age is exempt from prior authorization under KY-specific rules.
    • Children < 6 years: testing exempt from prior authorization.
    • KY limits: ≤35 presumptive and ≤16 definitive tests without prior authorization.
    • PA window: requests accepted up to 10 business days post-collection.
    Prior Authorization

    KY prior authorization protocol (submission window & pediatric exemption)

    KY-specific prior authorization protocol requires that testing for children <6 years is exempt from prior authorization and that prior authorization requests may be submitted up to 10 business days after specimen collection for medical necessity review based on the policy criteria.

    • Exemption: testing for children < 6 years does not require PA.
    • Submission window: PA requests accepted up to 10 business days after specimen collection and reviewed against criteria A, B, or C.
    Note

    Review Medicare NCDs/LCDs before applying policy

    For Medicare members, review all applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles before applying the criteria in this clinical policy to ensure consistency with Medicare coverage.

    • Refer to CMS (http://www.cms.gov) for applicable NCDs, LCDs, and Coverage Articles prior to applying this policy for Medicare members.
    Documentation Required

    Medical record documentation requirements for confirmatory testing

    The medical record must document a history or suspicion of illicit or prescription drug use, noncompliance, or a high probability of non-adherence and must include the rationale for confirmatory testing (e.g., prior presumptive test results, inconsistencies with expected results, need to identify precise drug(s), and why resolving inconsistencies is essential to ongoing care). Requests for serum therapeutic drug levels should document relation to medical treatment of a disease or condition.

    • Documented history or suspicion of drug use/noncompliance or high probability of non-adherence is required in the medical record.
    • Include prior presumptive test results and rationale (inconsistency with expected results or need to identify specific drug(s)).
    • For serum therapeutic levels, document relation to medical treatment (example: phenobarbital for seizures).
    Documentation Required

    Contractual binding of providers and members to plan terms

    Providers, members/enrollees, and their representatives are bound by the terms and conditions of their contracts and agree to be bound where no contract exists by providing services or submitting claims; documentation and coverage are governed by those contractual terms.

    • Contract terms and conditions govern coverage, documentation, and administration of benefits.
    • When state Medicaid provisions conflict with this policy, state Medicaid provisions take precedence.
    Denial Risk

    Denial risk: administrative, employment, school, and court-ordered testing

    Urine drug testing may be denied as not medically necessary when performed for employment/pre-employment, participation in school or athletic programs, or for medico-legal/court-ordered screening (unless required by state regulations); these and other listed administrative or blanket uses are considered not medically necessary.

    • Not medically necessary when performed as a condition of employment or pre-employment.
    • Not medically necessary for school, community athletic, or extracurricular participation.
    • Not medically necessary for court-ordered screening unless required by state regulations.
    Denial Risk

    Not medically necessary: blanket orders and reflex confirmatory testing

    The policy adds that blanket orders and reflex definitive testing following point-of-care presumptive testing are considered not medically necessary; testing must be individualized and meet medical necessity rather than performed automatically or by blanket/standing orders.

    • Blanket orders and physician standing orders for all patients are not medically necessary.
    • Reflex definitive tests when presumptive point-of-care testing was performed are not medically necessary.
    • Presumptive IA testing in a lab after POC presumptive testing, and using IA to confirm POC tests, are not medically necessary.
    Denial Risk

    Denial risk: coverage decisions subject to plan documents

    Coverage decisions and administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (evidence of coverage, certificate of coverage, policy, contract), which may affect authorization and denial determinations.

    • Decisions are governed by the member's coverage documents and applicable state/federal requirements.
    • This policy is a guide to medical necessity and does not guarantee payment.
    Documentation Required

    Documentation operational details for presumptive and definitive testing

    Ensure documentation supports that a presumptive test was performed when required by criteria (unless no reliable test exists) and that confirmatory testing is limited to specific drug(s) or drug classes indicated by preliminary analysis or clinical need.

    • If criteria A applies, document that a preliminary/presumptive test was previously performed unless no reliable test exists.
    • Confirmatory testing must be limited to the specific drug(s) or number of drug classes identified by preliminary analysis or expected positive results.
    Note

    Operational note: reflex and blanket orders not applicable

    Testing must be individualized and meet medical necessity criteria; automatic reflex testing, blanket orders, or routine standing orders that bypass clinical evaluation are not acceptable operational practices.

    • Testing driven by individualized clinical need per criteria A, B, or C only.
    • Blanket or reflex testing approaches are specifically excluded as not medically necessary.
    Note
    Clinical useOrdered when initial screening does not correlate with expected findings or when precise identification/quantification is clinically necessary.
    inv-33: Definitive testing detailed definition including use of stable isotope/internal standards and specimen validity testing
    Analytic requirementsDefinitive testing must use drug-identification methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS or LC/MS, single or tandem).
    Quality controlsMust employ stable isotope or other universally recognized internal standards in all samples and method/drug-specific calibration with matrix-matched quality control material to control for matrix effects and instrument variation.
    Scope of definitive testsMay be qualitative or quantitative and includes specimen validity testing; described per-day service units covering defined ranges of drug classes (e.g., 1-7, 15-21, 22+ classes reflected in HCPCS descriptors).
    inv-34: Definition — Health Plan
    Health Plan definitionHealth Plan means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.
    Policy roleThis clinical policy is a guide to medical necessity to assist coverage decisions and administering benefits; it is not a contract or guarantee of payment.
    GovernanceCoverage decisions remain subject to terms, conditions, exclusions, limitations of the coverage documents and applicable state/federal requirements.